

The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

The Board of Directors of Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has today resolved on the rights issue of units (shares and two series of warrants) of initially up to approximately SEK 47.4 million before deduction of transaction costs (the "Rights Issue"), the intention of which was announced through a press release on 19 May 2026. The Board of Directors' resolution on the Rights Issue, with preferential rights for the Company's existing shareholders, has been made pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026. The Rights Issue is covered by subscription commitments and underwriting commitments amounting to approximately SEK 33.15 million, corresponding to approximately 70 percent of the Rights Issue. The purpose of the Rights Issue is to finance the continued Medicare reimbursement approval process and commercialization activities in the United States and Europe.

Summary

- On 29 June 2026, the Board of Directors of Prostatype Genomics, pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026, resolved on the final terms of and approved the Rights Issue. Shareholders registered in the share register maintained by Euroclear Sweden AB as of the record date, 7 July 2026, will receive one (1) unit right for each share held on the record date. One (1) unit right entitles the holder to subscribe for one (1) unit. One (1) unit consists of eight (8) shares, two (2) warrants of series TO6 and four (4) warrants of series TO7.
- The subscription price amounts to SEK 0.80 per unit, corresponding to SEK 0.10 per share. Warrants of series TO6 and TO7 are issued free of charge. The subscription price in the Rights Issue corresponds to a TERP discount of approximately 30 percent, calculated on the basis of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during the period from and including 29 May 2026, up to and including 26 June 2026.
- Upon full subscription, the Rights Issue will provide Prostatype Genomics with approximately SEK 47.4 million before deduction of transaction costs. The net proceeds from the Rights Issue will be used to finance the Company's ongoing Medicare reimbursement approval process and commercialization activities in the United States and Europe.
- Provided that all warrants of series TO6 and TO7 are issued and exercised at their respective maximum exercise prices, the Company may receive additional proceeds of approximately SEK 59.2 million before deduction of transaction costs.

- The subscription period for the Rights Issue will run from 9 July 2026 up to and including 23 July 2026. The last day of trading in the Company's shares with the right to receive unit rights is 3 July 2026.
- The Rights Issue is covered by subscription commitments and underwriting commitments amounting to approximately SEK 33.15 million, corresponding to approximately 70 percent of the Rights Issue. Of the subscription commitments, which amount to approximately SEK 9.2 million in total, approximately SEK 7.4 million is intended to be settled through set-off against outstanding shareholder loans and accrued interest thereon. The remaining amount is intended to be settled in cash.
- The Company will prepare an information memorandum, which will be published no later than the day before the subscription period commences.

Background and use of proceeds

To further accelerate the commercialization and marketing of Prostatype Genomics' gene test, Prostatype®, in the United States, the Company is awaiting Medicare reimbursement approval. Since submitting its Medicare application, the Company has continuously responded to supplementary requests for information. The timing of such approval is difficult for the Company to estimate, as it depends on processes conducted by the relevant U.S. regulatory authorities. Throughout the process, the Company has worked closely with Swedish and U.S. legal advisers and, among other things, held an in-person meeting with representatives of Medicare during the second quarter of 2026. Based on the progress made in the process, the Company believes it is reasonable to expect that approval may be obtained during the current year. Upon receipt of Medicare reimbursement approval, the Board of Directors believes that Prostatype Genomics will be well positioned to commercialize Prostatype® in the United States.

To finance the above-mentioned development of the Company, as well as the repayment/conversion of outstanding bridge loans and accrued interest thereon, Prostatype Genomics is carrying out the Rights Issue, with a maximum issue size of approximately SEK 47.4 million (before transaction costs of approximately SEK 8.4 million, including cash compensation to the underwriters).

The maximum net proceeds from the Rights Issue are intended to be used for the following purposes:

- the Medicare reimbursement approval process;
- ongoing commercialization activities in the United States and Europe, as well as strengthening the Company's working capital and supporting ongoing operations; and
- repayment/conversion of bridge loans and accrued interest, as well as payment of outstanding trade payables.

The proceeds from the warrants of series T06 and T07 are intended to finance the scaling-up of the Company's commercial operations and organization in the United States, as well as ongoing operating expenses.

Subject to full subscription of the Rights Issue and full exercise of the warrants of series T06 and T07 at their respective maximum exercise prices, the Company expects the proceeds to fund its operations through the fourth quarter of 2027.

Rights Issue

Today, on 29 June 2026, the Board of Directors, pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026, resolved on the final terms of and approved the Rights Issue. Shareholders registered in the share register maintained by Euroclear Sweden AB as of the record date, 7 July 2026, will receive one (1) unit right for each share held on the record date. One (1) unit right entitles the holder to subscribe for one (1) unit. Each unit consists of eight (8) shares, two (2) warrants of series TO6 and four (4) warrants of series TO7 at a subscription price of SEK 0.80 per unit, corresponding to SEK 0.10 per share. Warrants of series TO6 and TO7 are issued free of charge.

Upon full subscription, the Rights Issue will initially provide the Company with approximately SEK 47.4 million before deduction of transaction costs. Provided that the Rights Issue is fully subscribed and all warrants of series TO6 are exercised at the maximum exercise price, the Company may receive additional proceeds of approximately SEK 11.9 million before deduction of transaction costs. Furthermore, provided that the Rights Issue is fully subscribed and all warrants of series TO7 are exercised at the maximum exercise price, the Company may receive additional proceeds of approximately SEK 47.4 million before deduction of transaction costs.

The subscription price in the Rights Issue of SEK 0.80 per unit, corresponding to SEK 0.10 per share, represents a TERP discount of approximately 30 percent, calculated on the basis of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during the period from and including 29 May 2026 up to and including 26 June 2026.

Upon full subscription of the Rights Issue, the Company's share capital will initially increase by SEK 47,351,456.80 to SEK 53,270,388.90 through the issuance of 473,514,568 new shares, resulting in the total number of outstanding shares in the Company increasing from 59,189,321 shares to 532,703,889 shares. Shareholders who choose not to participate in the Rights Issue will, assuming that the Rights Issue is fully subscribed, have their ownership diluted by approximately 88.9 percent. Such shareholders will, however, have the opportunity to compensate themselves financially for this dilution by selling their unit rights.

Upon full exercise of the warrants of series TO6, the share capital will increase by a further SEK 11,837,864.20 to SEK 65,108,253.10 through the issuance of 118,378,642 new shares, resulting in the total number of outstanding shares in the Company increasing from 532,703,889 shares (following the fully subscribed Rights Issue) to 651,082,531 shares. Shareholders who choose not to participate in the exercise of the warrants will, assuming that the warrants are exercised in full, have their ownership diluted by approximately 18.2 percent.

Upon full exercise of the warrants of series TO7, the share capital will increase by a further SEK 23,675,728.40 to SEK 88,783,981.50 through the issuance of 236,757,284 new shares, resulting in the total number of outstanding shares in the Company increasing from 651,082,531 shares (following the fully subscribed Rights Issue and full exercise of the TO6 warrants) to 887,839,815 shares. Shareholders who choose not to participate in the exercise of the warrants will, assuming that the warrants are exercised in full, have their ownership diluted by approximately 26.7 percent.

The subscription period for the Rights Issue will run from 9 July 2026 up to and including 23 July 2026. The last day of trading in the Company's shares with the right to receive unit rights is 3 July 2026.

For further information regarding the timetable, please refer to the section "Timetable for the Rights Issue" below.

Subscription commitments and underwriting commitments

The Company has received subscription commitments, with and without preferential rights, from a number of existing major shareholders, including members of the Board of Directors, amounting in aggregate to approximately SEK 9.2 million, corresponding to approximately 19.4 percent of the Rights Issue. Of these subscription commitments, approximately SEK 7.4 million is intended to be settled through set-off against outstanding shareholder loans and accrued interest thereon. The remaining amount is intended to be settled in cash. No compensation is payable in respect of the subscription commitments.

In addition, the Company has entered into an underwriting agreement with Vator Securities AB, on customary terms and conditions, amounting to approximately SEK 23.9 million, corresponding to approximately 50.6 percent of the Rights Issue. The underwriting commission amounts to 14 percent of the underwritten amount if paid in cash or, alternatively, 16 percent of the underwritten amount if the underwriter elects to receive compensation in the form of units in the Company. Vator Securities AB holds the necessary authorization to act as an underwriter and has entered into separate option agreements with a number of investors regarding the transfer of any units that may be allotted pursuant to the fulfilment of the underwriting commitment.

In total, the Rights Issue is covered by subscription commitments and underwriting commitments amounting to approximately SEK 33.15 million, corresponding to approximately 70 percent of the Rights Issue. The underwriting commitment constitutes a so-called bottom underwriting commitment, covering subscriptions up to approximately 70 percent of the Rights Issue. Neither the subscription commitments nor the underwriting commitment are secured by bank guarantees, blocked funds, pledges or similar arrangements.

Should the underwriter elect to receive the underwriting commission in the form of units, the Board of Directors intends to resolve on a directed issue of such units to the underwriter. The terms and conditions of any such directed issue to the underwriter will correspond to those of the Rights Issue.

Warrants of series T06

The warrants of series T06 will be issued free of charge. Each (1) T06 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise price for warrants of series T06 will be SEK 0.10 per share, corresponding to both the subscription price per share in the Rights Issue and the share's quota value.

The T06 warrants may be exercised for subscription of new shares in Prostatype Genomics during the period from 1 September 2026 up to and including 15 September 2026. The T06 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the T06 warrants is expected to be 11 September 2026.

Upon full exercise of all T06 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 11.8 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 0.6 million.

The complete terms and conditions for the T06 warrants will be available on the Company's website.

Warrants of series T07

The warrants of series T07 will be issued free of charge. Each (1) T07 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise period for the T07 warrants is event-driven and is contingent upon the Company obtaining Medicare reimbursement approval.

The exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during a measurement period comprising the ten (10) trading days preceding the Company's announcement of Medicare reimbursement approval. However, the exercise price shall not be lower than SEK 0.10 per share and not higher than SEK 0.20 per share.

As the primary alternative, an exercise period of ten (10) trading days shall commence three (3) trading days after the Company has announced, by way of a press release, that its Medicare application has been approved, but no earlier than 1 September 2026 and no later than 7 December 2026.

Alternatively, if approval of the Company's Medicare application has not been announced and no exercise period has been determined within the timeframe set out above, the exercise period shall commence on 7 December 2026 and remain open for ten (10) trading days, up to and including 21 December 2026. In such case, the exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company's share during the ten (10) trading days ending two trading days prior to the commencement of the exercise period on 7 December 2026.

Accordingly, the ten (10) trading day exercise period for the T07 warrants may commence no earlier than 1 September 2026 and no later than 7 December 2026.

Upon full exercise of all T07 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 47.4 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 2.2 million.

The T07 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the T07 warrants is expected to be no later than 17 December 2026.

The complete terms and conditions for the T07 warrants will be available on the Company's website.

Directed issue in the event of oversubscription

In the event that the Rights Issue is oversubscribed and persons or entities that have entered into subscription commitments without preferential rights are not allocated units, in whole or in part, to an extent sufficient to fulfil their commitments, the Company intends to resolve on a separate directed issue of units (a so-called over-allotment issue). The terms and conditions of any such directed issue of units will correspond to those of the Rights Issue.

Timetable for the Rights Issue

- Last day of trading in Prostatype Genomics shares including the right to receive unit rights: 3 July 2026.
- First day of trading in Prostatype Genomics shares excluding the right to receive unit rights: 6 July 2026.
- Record date for participation in the Rights Issue: 7 July 2026.
- Subscription period: 9-23 July 2026.
- Trading in unit rights: 9-20 July 2026.
- Trading in BTUs: from and including 9 July 2026 until the Rights Issue has been registered with the Swedish Companies Registration Office. Estimated around 10 August 2026. The last day of trading in BTUs will be announced through a separate press release after completion of the Rights Issue.
- Press release announcing the outcome of the Rights Issue: around 24 July 2026.
- First day of trading in TO6 and TO7: around 14 August 2026.

Information memorandum

An information memorandum containing the complete terms and conditions of the Rights Issue will be published through a separate press release no later than the day before the subscription period commences and will be available on the Company's website (www.prostatypegenomics.com).

Information to investors pursuant to the Swedish Foreign Direct Investment Screening Act (2023:560)

As the Company conducts activities deemed worthy of protection under the Swedish Foreign Direct Investment Screening Act (2023:560), certain investments in the Rights Issue may need to be reviewed by the Inspectorate of Strategic Products (ISP). For more information, please visit the ISP website, www.isp.se, or contact the Company.

Advisors

Navia Corporate Finance AB and Birchtree Advisory AB are financial advisors and Bookrunners in connection with the Rights Issue. Advokatfirman Lindahl is the legal advisor. Vator Securities AB is the issuing agent.

For more information about the Rights Issue, please contact:

Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

or

Birchtree Advisory AB
E-mail: jonas.bjorkman@birchtreeadvisory.se
Website: www.birchtreeadvisory.se

For more information about the Company, please contact:

Fredrik Rickman, VD Prostatype Genomics AB
Phone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser

Tapper Partners AB
Phone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se

About Prostatype Genomics

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Prostatype Genomics. No action has been taken, and no action will be taken, to permit an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics will only be made through the information memorandum that Prostatype Genomics intends to publish before the subscription period commences.

The information in this press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or require measures other than those required under Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold, or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States. This press release is distributed and directed only to persons in the United Kingdom who are (i) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth entities and other persons to whom this press release may lawfully be communicated, falling within Article 49(2)(a)-(d) of the Order (all such persons together being referred to as "Relevant Persons"). Persons who are not Relevant Persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will only be engaged in with Relevant Persons. Persons distributing this communication must satisfy themselves that such distribution is lawful.

Forward-looking statements

This press release contains forward-looking statements concerning the Company's intentions, assessments, or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and may be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "assumes," "should," "could," and, in each case, their negative forms, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or prove to be correct. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may differ materially from those expressed in the forward-looking statements for a variety of reasons.

Such risks, uncertainties, unforeseen events, and other significant factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct, and readers of this press release should not place undue reliance on the forward-looking statements contained herein. The information, opinions, and forward-looking statements expressed or implied in this press release speak only as of the date of this press release and are subject to change. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the contents of this press release, except as required by law or the Nasdaq First North Growth Market Rulebook for Issuers.